Trial · NCT03110770
Participant flow30
How many started, completed or left each group, period by period.
1 to 20 of 30
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | 30 | |
| Overall Study | STARTED | Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections | 30 | |
| Overall Study | STARTED | Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections | 30 | |
| Overall Study | STARTED | Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | 1,170 | |
| Overall Study | STARTED | Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections | 1,168 | |
| Overall Study | Received First Product Administration | Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | 30 | |
| Overall Study | Received First Product Administration | Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections | 30 | |
| Overall Study | Received First Product Administration | Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections | 30 | |
| Overall Study | Received First Product Administration | Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | 1,162 | |
| Overall Study | Received First Product Administration | Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections | 1,161 | |
| Overall Study | Received Second Product Administration | Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | 30 | |
| Overall Study | Received Second Product Administration | Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections | 29 | |
| Overall Study | Received Second Product Administration | Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections | 29 | |
| Overall Study | Received Second Product Administration | Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | 1,126 | |
| Overall Study | Received Second Product Administration | Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections | 1,127 | |
| Overall Study | Received Third Product Administration | Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | 29 | |
| Overall Study | Received Third Product Administration | Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections | 27 | |
| Overall Study | Received Third Product Administration | Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections | 28 | |
| Overall Study | Received Third Product Administration | Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | 1,107 | |
| Overall Study | Received Third Product Administration | Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections | 1,107 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03110770/flow